Pfizer Confirms 2024-2025 Revenue Projections

Pfizer has confirmed its full-year 2024 and 2025 revenue projections, forecasting between $61 billion to $64 billion in sales, aligning closely with analysts' estimates. The pharmaceutical giant expects 2025 adjusted earnings per share (EPS) to range from $2.80 to $3.00, indicating a potential growth of 10% to 18% year-over-year from the midpoint of their 2024 guidance. Despite a challenging year with a decline in COVID-19 product sales and investor criticism, particularly from Starboard Value, Pfizer remains focused on cost-cutting and financial discipline, having already achieved $4 billion in savings. The company anticipates an additional $500 million in savings through 2025 and is working on new drugs like danuglipron, an oral GLP-1 receptor agonist for weight loss. Pfizer's shares rose in response to the guidance, although they remain down for the year. Overall, the company's projections aim to stabilize its position and address investor concerns over past management and operational decisions.